Evidence map›Paper›PMID 38605095›Full record

ArticleScientific reports2024

Cas9-directed long-read sequencing to resolve optical genome mapping findings in leukemia diagnostics.

Eddy N de Boer, Vincent Vroom, Arjen J Scheper, Lennart F Johansson, Laura Bosscher, Nettie Rietema, Sabrina Z Commandeur-Jan, Nine V A M Knoers, Birgit Sikkema-Raddatz, Eva van den Berg and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eddy N de BoerDepartment of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. e.n.de.boer@umcg.nl.
Vincent Vroom *Department of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Arjen J Scheper *Department of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Lennart F JohanssonDepartment of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Laura BosscherDepartment of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Nettie RietemaDepartment of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Sabrina Z Commandeur-JanDepartment of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Nine V A M KnoersDepartment of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Birgit Sikkema-RaddatzDepartment of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Eva van den Berg *Department of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Cleo C van Diemen *Department of Genetics, University of Groningen, University Medical Center Groningen, CB51, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukemias are genetically heterogeneous and diagnostics therefore includes various standard-of-care (SOC) techniques, including karyotyping, SNP-array and FISH. Optical genome mapping (OGM) may replace these as it detects different types of structural aberrations simultaneously and additionally detects much smaller aberrations (500 bp vs 5-10 Mb with karyotyping). However, its resolution may still be too low to define clinical relevance of aberrations when they are located between two OGM labels or when labels are not distinct enough. Here, we test the potential of Cas9-directed long-read sequencing (LRS) as an additional technique to resolve such potentially relevant new findings. From an internal Bionano implementation study we selected ten OGM calls that could not be validated with SOC methods. Per variant we designed crRNAs for Cas9 enrichment, prepared libraries and sequenced them on a MinION/GridION device. We could confirm all aberrations and, importantly, the actual breakpoints of the OGM calls were located between 0.2 and 5.5 kb of the OGM-estimated breakpoints, confirming the high reliability of OGM. Furthermore, we show examples of redefinition of aberrations between labels that enable judgment of clinical relevance. Our results suggest that Cas9-directed LRS can be a relevant and flexible secondary technique in diagnostic workflows including OGM.

Indexed as

CRISPR-Cas SystemsLeukemiaChromosome MappingHumansKaryotypingReproducibility of Results

Identifiers

PMID38605095
PMCPMC11009395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.